{"brief_title": "An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)", "brief_summary": "The purpose of this study is to look at whether an investigational drug can treat the breathing symptoms of RSV bronchiolitis in children 3 to 24 months of age.", "condition": "Bronchiolitis", "intervention_type": "Drug", "intervention_name": "Comparator: placebo", "description": "Duration of Treatment: 6 months", "other_name": "MK0476", "criteria": "Inclusion Criteria: - Hospitalized or in an urgent/emergent-care setting at least 24 hours for a first or second episode of RSV-induced bronchiolitis. Approximately twenty percent of patients will be allowed in the study with a stay of less than 24 hours but need to meet a minimum predefined Respiratory Severity Score as required by the study. Exclusion Criteria: - Asthma or other wheezing disorder. The Primary Investigator will evaluate whether there are other reasons why a child may not participate.", "gender": "All", "minimum_age": "3 Months", "maximum_age": "24 Months", "healthy_volunteers": "No", "id": "NCT00076973.xml"}